LLYEli Lilly and CompanyFinished
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Desmoplastic Small Round Cell Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 30 (final count)
- Started
- Jan 22, 2020
- Main results expected
- Jun 14, 2024
- Fully finished
- Jan 23, 2026
- Results posted
- Jul 20, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: Randomization to Objective Progression or Death Due to Any Cause (Up To 23 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04145349 · record last updated 2026-08-07 · checked 2026-11-09 15:36 UTC